Literature DB >> 1647071

Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors.

S Morikawa1, T F Booth, D H Bishop.   

Abstract

Feline immunodeficiency virus (FIV) gag gene was expressed in baculovirus vectors to investigate its potential for the assembly of virus-like particles. The unprocessed 50-kDa FIV gag precursor made in infected insect cells by recombinant AcFIVGAG-1 was myristoylated, assembled at the cell surface into virus-like particles (with diameters of approximately 100 nm), and efficiently released into the culture supernatant fluids. The presence of the complete viral-coded protease component of the FIV pol gene engineered into a second expression vector (AcFIVGAG-P5) resulted in the efficient processing of the gag precursor to its component proteins and abolished particle formation and secretion. Insertion of a stop codon in this vector upstream of the putative gag-pol frameshift site (GGGAAAC) resulted in the derivation of an expression vector (AcFIVGAG-R) that made a truncated, unprocessed 46-kDa FIV gag precursor lacking some 34 amino acids in the p10 carboxy-proximal coding region of gag. This vector synthesized tubular structures in the cytoplasm of infected cells and released them into the cell supernatant. The results demonstrate that the FIV gag precursor can spontaneously assemble into virus-like particles without any other virus proteins and that the carboxy-terminal part of the precursor gag protein is essential for such assembly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647071     DOI: 10.1016/0042-6822(91)90141-w

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Translational suppressors and antisuppressors alter the efficiency of the Ty1 programmed translational frameshift.

Authors:  C L Burck; Y O Chernoff; R Liu; P J Farabaugh; S W Liebman
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

2.  PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells.

Authors:  M C Johnson; H M Scobie; V M Vogt
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 3.  Virus maturation by budding.

Authors:  H Garoff; R Hewson; D J Opstelten
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

4.  Expression of feline immunodeficiency virus gag and env precursor proteins in Spodoptera frugiperda cells and their use in immunodiagnosis.

Authors:  E J Verschoor; A L van Vliet; H F Egberink; W Hesselink; M C Horzinek; A de Ronde
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

5.  Phylogenetic analysis of the long terminal repeat of feline immunodeficiency viruses from Japan, Argentina and Australia.

Authors:  H Yamada; T Miyazawa; K Tomonaga; Y Kawaguchi; K Maeda; M C Castellano; C Kai; Y Tohya; T Mikami
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Specificity of Rous sarcoma virus nucleocapsid protein in genomic RNA packaging.

Authors:  P Dupraz; P F Spahr
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

8.  Altered cell tropism and cytopathicity of feline immunodeficiency viruses in two different feline CD4-positive, CD8-negative cell lines.

Authors:  K Tokunaga; Y Nishino; H Oikawa; C Ishihara; T Mikami; K Ikuta
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 9.  The use of baculoviruses as expression vectors.

Authors:  I M Kidd; V C Emery
Journal:  Appl Biochem Biotechnol       Date:  1993 Aug-Sep       Impact factor: 2.926

Review 10.  The genome of feline immunodeficiency virus.

Authors:  T Miyazawa; K Tomonaga; Y Kawaguchi; T Mikami
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.